Latin American consensus recommendations on the risk of infections in people with multiple sclerosis treated with disease modifying drugs-Reference-Cited by-同舟云学术

Latin American consensus recommendations on the risk of infections in people with multiple sclerosis treated with disease modifying drugs

Published:2023-09 Issue: Volume:77 Page:104840
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Silva Berenice A.,Carnero Contentti Edgar,Becker Jefferson,Carranza José I,Correa-Díaz Patricio E,Galleguillos Goiry Lorna,Garcea Orlando,Gracia Fernando,Hamuy Fernando,Macías Miguel Angel,Navas Carlos,Nuñez Sebastián,Rojas Juan I,Farez Mauricio F.,Alonso Ricardo,López Pablo

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference128 articles.

1. Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab;Aguirre;Multiple sclerosis and related disorders,2019

2. Dengue fever in a multiple sclerosis patient taking ocrelizumab: Clinical commentary;Alonso;Multiple sclerosis,2021

3. COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM;Alonso;Multiple sclerosis and related disorders,2021

4. SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry;Arrambide;Neurology(R) neuroimmunology & neuroinflammation,2021

5. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management;Arvin;JAMA Neurol,2015

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of high efficacy therapies in older people with Multiple Sclerosis: A real-world evidence study;Multiple Sclerosis and Related Disorders;2024-10

2. Latent tuberculosis prevalence, diagnosis and treatment in Multiple Sclerosis as a strategy for reducing infection reactivation during immunosuppressant therapy;Multiple Sclerosis and Related Disorders;2024-06

3. Comorbilidades en la esclerosis múltiple y su influencia en la elección del tratamiento;Revista de Neurología;2024